Artiva reports 2024 net loss of $65.4M; cash $185.4M; autoimmune data expected H1 2025

Artiva Biotherapeutics, Inc.

Net loss of $65.4M in 2024 vs net income of $28.7M in 2023; no collaboration revenue vs $32.9M prior year.
Cash, cash equivalents and investments $185.4M at Dec 31, 2024, expected to fund operations through end of 2026.
Initial data from AlloNK (AB-101) in autoimmune indications (SLE/LN, RA) expected in H1 2025.
Appointed Dan Baker to Board and added SVP-level leadership in Regulatory, Clinical Ops, and Biometrics.
Updated Phase 1/2 NHL trial data for AlloNK + rituximab showing durability to be presented at 2025 medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.